Evaluating children with autoimmune central nervous system disorders using spinal fluid specimens
Test Id | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
PCCI | Peds Autoimmune CNS Interp, CSF | No | Yes |
ANN1C | Anti-Neuronal Nuclear Ab, Type 1 | No | Yes |
CS2CC | CASPR2-IgG CBA, CSF | No | Yes |
DPPIC | DPPX Ab IFA, CSF | No | Yes |
GABCC | GABA-B-R Ab CBA, CSF | No | Yes |
GD65C | GAD65 Ab Assay, CSF | Yes | Yes |
GFAIC | GFAP IFA, CSF | No | Yes |
LG1CC | LGI1-IgG CBA, CSF | No | Yes |
GL1IC | mGluR1 Ab IFA, CSF | No | Yes |
NMDCC | NMDA-R Ab CBA, CSF | No | Yes |
NMOFC | NMO/AQP4 FACS, CSF | Yes | Yes |
PCTRC | Purkinje Cell Cytoplasmc Ab Type Tr | No | Yes |
Test Id | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
AGN1C | Anti-Glial Nuclear Ab, Type 1 | No | No |
AGNBC | AGNA-1 Immunoblot, CSF | No | No |
AMIBC | Amphiphysin Immunoblot, CSF | No | No |
AMPCC | AMPA-R Ab CBA, CSF | No | No |
AMPHC | Amphiphysin Ab, CSF | No | No |
AMPIC | AMPA-R Ab IF Titer Assay, CSF | No | No |
AN1BC | ANNA-1 Immunoblot, CSF | No | No |
AN2BC | ANNA-2 Immunoblot, CSF | No | No |
ANN2C | Anti-Neuronal Nuclear Ab, Type 2 | No | No |
ANN3C | Anti-Neuronal Nuclear Ab, Type 3 | No | No |
DPPCC | DPPX Ab CBA, CSF | No | No |
DPPTC | DPPX Ab IFA Titer, CSF | No | No |
GABIC | GABA-B-R Ab IF Titer Assay, CSF | No | No |
GFACC | GFAP CBA, CSF | No | No |
GFATC | GFAP IFA Titer, CSF | No | No |
GL1CC | mGluR1 Ab CBA, CSF | No | No |
GL1TC | mGluR1 Ab IFA Titer, CSF | No | No |
NMDIC | NMDA-R Ab IF Titer Assay, CSF | No | No |
NMOTC | NMO/AQP4 FACS Titer, CSF | No | No |
PC1BC | PCA-1 Immunoblot, CSF | No | No |
PCA1C | Purkinje Cell Cytoplasmic Ab Type 1 | No | No |
PCA2C | Purkinje Cell Cytoplasmic Ab Type 2 | No | No |
PCTBC | PCA-Tr Immunoblot, CSF | No | No |
If indirect immunofluorescence assay (IFA) patterns suggest antineuronal nuclear antibodies (ANNA)-1, then ANNA-1 immunoblot and ANNA-2 immunoblot are performed at an additional charge.
If IFA patterns suggest ANNA-2 antibody, then ANNA-2 immunoblot, ANNA-1 immunoblot, and ANNA-2 antibody IFA are performed at an additional charged.
If IFA patterns suggest ANNA-3 antibody, then ANNA-3 IFA is performed at an additional charge.
If IFA patterns suggest Purkinje cytoplasmic antibody (PCA)-1, then PCA-1 immunoblot and PCA-1 IFA are performed at an additional charge.
If IFA patterns suggest PCA-2 antibody, then PCA-2 IFA is performed at an additional charge.
If IFA patterns suggest PCA-Tr antibody, then PCA-Tr immunoblot is performed at an additional charge.
If IFA pattern suggests amphiphysin antibody, then amphiphysin immunoblot and amphiphysin antibody IFA titer are performed at an additional charge.
If IFA pattern suggests anti-glial nuclear antibody (AGNA), then AGNA immunoblot and AGNA antibody IFA titer are performed at an additional charge.
If IFA pattern suggests N-methyl-D-aspartate receptor (NMDA-R) antibody, then NMDA-R IFA titer is performed at an additional charge.
If IFA pattern suggests alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPA-R) antibody, then AMPA-R antibody cell-binding assay (CBA) and AMPA-R IFA are performed at an additional charge.
If IFA pattern suggests gamma-aminobutyric acid B receptor (GABA-B-R) antibody, then GABA-B-R IFA titer is performed at an additional charge.
If IFA pattern suggests dipeptidyl-peptidase-like protein-6 (DPPX) antibody, then DPPX antibody CBA and DPPX IFA titer are performed at an additional charge.
If IFA pattern suggests metabotropic glutamate receptor 1 (mGluR1) antibody, then mGluR1antibody CBA and mGluR1 IFA titer are performed at an additional charge.
If IFA pattern suggests glial fibrillary acidic protein (GFAP) antibody, then GFAP antibody CBA and GFAP IFA titer are performed at an additional charge.
If neuromyelitis optica/aquaporin-4-IgG (NMO/AQP4-IgG) fluorescence-activated cell sorting (FACS) screen assay requires further investigation, then NMO/AQP4-IgG FACS titration assay is performed at an additional charge.
For more information, see the following:
Pediatric Autoimmune Central Nervous System Demyelinating Disease Diagnostic Algorithm
CS2CC, DPPCC, GABCC, AMPCC, GFACC, GL1CC, LG1CC, NMDCC: Cell-Binding Assay (CBA)
NMOFC, NMOTC: Flow Cytometry
AGN1C, AMPIC, ANN1C, ANN2C, ANN3C, DPPIC, DPPTC, GABIC, GFAIC, GFATC, GL1IC, GL1TC, NMDIC, PCA1C, PCA2C, PCTRC: Indirect Immunofluorescence (IFA)
GD65C: Radioimmunoassay (RIA)
AGNBC, AMIBC, AN1BC, AN2BC, PC1BC, PC2BC: Immunoblot (IB)
Encephalitis
Myelitis
Encephalopathy
Myelopathy, pediatric
Myelopathy, child
If indirect immunofluorescence assay (IFA) patterns suggest antineuronal nuclear antibodies (ANNA)-1, then ANNA-1 immunoblot and ANNA-2 immunoblot are performed at an additional charge.
If IFA patterns suggest ANNA-2 antibody, then ANNA-2 immunoblot, ANNA-1 immunoblot, and ANNA-2 antibody IFA are performed at an additional charged.
If IFA patterns suggest ANNA-3 antibody, then ANNA-3 IFA is performed at an additional charge.
If IFA patterns suggest Purkinje cytoplasmic antibody (PCA)-1, then PCA-1 immunoblot and PCA-1 IFA are performed at an additional charge.
If IFA patterns suggest PCA-2 antibody, then PCA-2 IFA is performed at an additional charge.
If IFA patterns suggest PCA-Tr antibody, then PCA-Tr immunoblot is performed at an additional charge.
If IFA pattern suggests amphiphysin antibody, then amphiphysin immunoblot and amphiphysin antibody IFA titer are performed at an additional charge.
If IFA pattern suggests anti-glial nuclear antibody (AGNA), then AGNA immunoblot and AGNA antibody IFA titer are performed at an additional charge.
If IFA pattern suggests N-methyl-D-aspartate receptor (NMDA-R) antibody, then NMDA-R IFA titer is performed at an additional charge.
If IFA pattern suggests alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPA-R) antibody, then AMPA-R antibody cell-binding assay (CBA) and AMPA-R IFA are performed at an additional charge.
If IFA pattern suggests gamma-aminobutyric acid B receptor (GABA-B-R) antibody, then GABA-B-R IFA titer is performed at an additional charge.
If IFA pattern suggests dipeptidyl-peptidase-like protein-6 (DPPX) antibody, then DPPX antibody CBA and DPPX IFA titer are performed at an additional charge.
If IFA pattern suggests metabotropic glutamate receptor 1 (mGluR1) antibody, then mGluR1antibody CBA and mGluR1 IFA titer are performed at an additional charge.
If IFA pattern suggests glial fibrillary acidic protein (GFAP) antibody, then GFAP antibody CBA and GFAP IFA titer are performed at an additional charge.
If neuromyelitis optica/aquaporin-4-IgG (NMO/AQP4-IgG) fluorescence-activated cell sorting (FACS) screen assay requires further investigation, then NMO/AQP4-IgG FACS titration assay is performed at an additional charge.
For more information, see the following:
Pediatric Autoimmune Central Nervous System Demyelinating Disease Diagnostic Algorithm
CSF
Multiple neuroimmunology profile tests are available. For testing that is performed with each profile, see Autoimmune Neurology Antibody Matrix.
Provide the following information:
-Relevant clinical information
-Ordering provider name, phone number, mailing address, and e-mail address
Container/Tube: Sterile vial
Specimen Volume: 4 mL
If not ordering electronically, complete, print, and send a Neurology Specialty Testing Client Test Request (T732) with the specimen.
2 mL
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
CSF | Refrigerated (preferred) | 28 days | |
Frozen | 28 days | ||
Ambient | 72 hours |
Evaluating children with autoimmune central nervous system disorders using spinal fluid specimens
If indirect immunofluorescence assay (IFA) patterns suggest antineuronal nuclear antibodies (ANNA)-1, then ANNA-1 immunoblot and ANNA-2 immunoblot are performed at an additional charge.
If IFA patterns suggest ANNA-2 antibody, then ANNA-2 immunoblot, ANNA-1 immunoblot, and ANNA-2 antibody IFA are performed at an additional charged.
If IFA patterns suggest ANNA-3 antibody, then ANNA-3 IFA is performed at an additional charge.
If IFA patterns suggest Purkinje cytoplasmic antibody (PCA)-1, then PCA-1 immunoblot and PCA-1 IFA are performed at an additional charge.
If IFA patterns suggest PCA-2 antibody, then PCA-2 IFA is performed at an additional charge.
If IFA patterns suggest PCA-Tr antibody, then PCA-Tr immunoblot is performed at an additional charge.
If IFA pattern suggests amphiphysin antibody, then amphiphysin immunoblot and amphiphysin antibody IFA titer are performed at an additional charge.
If IFA pattern suggests anti-glial nuclear antibody (AGNA), then AGNA immunoblot and AGNA antibody IFA titer are performed at an additional charge.
If IFA pattern suggests N-methyl-D-aspartate receptor (NMDA-R) antibody, then NMDA-R IFA titer is performed at an additional charge.
If IFA pattern suggests alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPA-R) antibody, then AMPA-R antibody cell-binding assay (CBA) and AMPA-R IFA are performed at an additional charge.
If IFA pattern suggests gamma-aminobutyric acid B receptor (GABA-B-R) antibody, then GABA-B-R IFA titer is performed at an additional charge.
If IFA pattern suggests dipeptidyl-peptidase-like protein-6 (DPPX) antibody, then DPPX antibody CBA and DPPX IFA titer are performed at an additional charge.
If IFA pattern suggests metabotropic glutamate receptor 1 (mGluR1) antibody, then mGluR1antibody CBA and mGluR1 IFA titer are performed at an additional charge.
If IFA pattern suggests glial fibrillary acidic protein (GFAP) antibody, then GFAP antibody CBA and GFAP IFA titer are performed at an additional charge.
If neuromyelitis optica/aquaporin-4-IgG (NMO/AQP4-IgG) fluorescence-activated cell sorting (FACS) screen assay requires further investigation, then NMO/AQP4-IgG FACS titration assay is performed at an additional charge.
For more information, see the following:
Pediatric Autoimmune Central Nervous System Demyelinating Disease Diagnostic Algorithm
Autoimmune encephalitis and myelitis is increasingly recognized as a cause of central nervous system disease in children and adolescents. N-methyl-D-aspartate receptor antibody (NMDA-R) encephalitis and myelin oligodendrocyte glycoprotein (MOG) autoimmunity are most common, although other entities, including aquaporin-4 autoimmunity, contactin-associated protein-like 2 (CASPR2) autoimmunity, autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy, and paraneoplastic encephalomyelopathies, may also occur in children.
Test ID | Reporting Name | Methodology | Reference Value |
PCCI | Peds Autoimmune CNS Interp, CSF | Medical interpretation | NA |
ANN1C | Anti-Neuronal Nuclear Ab, Type 1 | IFA | Negative at <1:2* |
CS2CC | CASPR2-IgG CBA, CSF | CBA | Negative |
DPPIC | DPPX Ab IFA, CSF | IFA | Negative |
GABCC | GABA-B-R Ab CBA, CSF | CBA | Negative |
GD65C | GAD65 Ab Assay, CSF | RIA | < or =0.02 nmol/L Reference values apply to all ages. |
GFAIC | GFAP IFA, CSF | IFA | Negative |
GL1IC | mGluR1 Ab IFA, CSF | IFA | Negative |
LG1CC | LGI1-IgG CBA, CSF | CBA | Negative |
NMDCC | NMDA-R Ab CBA, CSF | CBA | Negative |
NMOFC | NMO/AQP4 FACS, CSF | FACS | Negative |
PCTRC | Purkinje Cell Cytoplasmc Ab Type Tr | IFA | <1:2* |
Reflex Information:
Test ID | Reporting Name | Methodology | Reference Value |
AGN1C | Anti-Glial Nuclear Ab Type 1 | IFA | <1:2 |
AGNBC | AGNA-1 Immunoblot, CSF | IB | Negative |
AMIBC | Amphiphysin Immunoblot, CSF | IB | Negative |
AMPCC | AMPA-R Ab CBA, CSF | CBA | Negative |
AMPHC | Amphiphysin Ab, CSF | IFA | <1:2 |
AMPIC | AMPA-R Ab IF Titer Assay, CSF | IFA | <1:2 |
ANN2C | Anti-Neuronal Nuclear Ab, Type 2 | IFA | <1:2* |
AN1BC | ANNA-1 Immunoblot, CSF | IB | Negative |
AN2BC | ANNA-2 Immunoblot, CSF | IB | Negative |
ANN3C | Anti-Neuronal Nuclear Ab, Type 3 | IFA | <1:2* |
DPPCC | DPPX Ab CBA, CSF | CBA | Negative |
DPPTC | DPPX Ab IFA Titer, CSF | IFA | <1:2 |
GABIC | GABA-B-R Ab IF Titer Assay, CSF | IFA | <1:2 |
GFACC | GFAP CBA, CSF | CBA | Negative |
GFATC | GFAP IFA Titer, CSF | IFA | <1:2 |
GL1CC | mGluR1 Ab CBA, CSF | CBA | Negative |
GL1TC | mGluR1 Ab IFA Titer, CSF | IFA | <1:2 |
NMDIC | NMDA-R Ab IF Titer Assay, CSF | IFA | <1:2 |
NMOTC | NMO/AQP4 FACS Titer, CSF | FACS | <1:2 |
PC1BC | PCA-1 Immunoblot, CSF | IB | Negative |
PCA1C | Purkinje Cell Cytoplasmic Ab Type 1 | IFA | <1:2* |
PCA2C | Purkinje Cell Cytoplasmic Ab Type 2 | IFA | <1:2* |
PCTBC | PCA-Tr Immunoblot, CSF | IB | Negative |
*Methodology abbreviations:
Immunofluorescence assay (IFA)
Cell-binding assay (CBA)
Fluorescence activated cell sorting assay (FACS)
Radioimmunoassay (RIA)
Immunoblot (IB)
*Neuron-restricted patterns of IgG staining that do not fulfill criteria for ANNA-1, ANNA-2, ANNA-3, PCA-1, PCA-2, or PCA-Tr may be reported as "unclassified antineuronal IgG." Complex patterns that include nonneuronal elements may be reported as "uninterpretable."
This profile is consistent with an autoimmune central nervous system disorder.
Negative results do not exclude a diagnosis of an autoimmune central nervous system disorder.
1. Dubey D, Pittock SJ, Krecke KN, et al: Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol. 2019 Mar 1;76(3):301-309 doi: 10.1001/jamaneurol.2018.4053
2. McKeon A, Lennon VA, Lotze T, et al: CNS aquaporin-4 autoimmunity in children. Neurology. 2008 Jul 8;71(2):93-100
3. Dubey D, Hinson SR, Jolliffe EA, et al: Autoimmune GFAP astrocytopathy: Prospective evaluation of 90 patients in 1?year. J Neuroimmunol. 2018 Aug 15;321:157-163
4. Philipps G, Alisanski SB, Pranzatelli M, et al: Purkinje cell cytoplasmic antibody type 1 (anti-Yo) autoimmunity in a child with Down syndrome. JAMA Neurol. 2014 Mar;71(3):347-349
5. Lopez-Chiriboga AS, Klein C, Zekeridou A, et al: LGI1 and CASPR2 neurological autoimmunity in children. Ann Neurol. 2018 Sep;84(3):473-480
6. Lopez-Chiriboga AS, Majed M, Fryer J, et al: Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders. JAMA Neurol. 2018 Nov 1;75(11):1355-1363
7. Clardy SL, Lennon VA, Dalmau J: Childhood onset of stiff-man syndrome. JAMA Neurol. 2013 Dec;70(12):1531-1536
8. Banwell B, Tenembaum S, Lennon VA, et al: Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology. 2008 Jan 29;70(5):344-352
Indirect Immunofluorescence Assay :
Before testing, patient's spinal fluid (CSF) is preabsorbed with liver powder to remove nonorgan-specific autoantibodies. After applying to a composite substrate of frozen mouse tissues (brain, kidney, and gut) and washing, fluorescein-conjugated goat-antihuman IgG is applied to detect the distribution and pattern of patient IgG binding.(Pittock SJ, Kryzer TJ, Lennon VA: Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 2004;56:715-719; Basal E, Zalewski N, Kryzer TJ, et al: Paraneoplastic neuronal intermediate filament autoimmunity. Neurology. 2018 Oct 30;91[18]:e1677-e1689)
Radioimmunoassay :
Goat-antihuman IgG and IgM is used as precipitant in all assays. Cation channel protein antigens are solubilized from neuronal or muscle membrane, in nonionic detergent, and complexed with a selective high-affinity ligand labeled with (125)I. (125)I-labelled recombinant human glutamic acid decarboxylase-65 (GAD65) antigen is used to confirm GAD65 autoantibody (when suspected from immunofluorescent staining pattern).(Griesmann GE, Kryzer TJ, Lennon VA: Autoantibody profiles of myasthenia gravis and Lambert-Eaton myasthenic syndrome. In Manual of Clinical and Laboratory Immunology. Sixth edition. Edited by NR Rose, RG Hamilton, et al. Washington, DC, ASM Press, 2002, pp 1005-1012; Walikonis JE, Lennon VA: Radioimmunoassay for glutamic acid decarboxylase [GAD65] autoantibodies as a diagnostic aid for stiff-man syndrome and a correlate of susceptibility to type 1 diabetes mellitus. Mayo Clin Proc 1998;73[12]:1161-1166; Jones AL, Flanagan EP, Pittock SJ, et al: Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults. JAMA Neurol. 2015 Nov;72[11]:1304-1312 doi: 10.1001/jamaneurol.2015.2378)
Cell-Binding Assay :
Patient CSF is applied to a composite slide containing transfected and nontransfected HEK-293 cells. After incubation and washing, fluorescein-conjugated goat-antihuman IgG is applied to detect the presence of patient IgG binding.( Package insert: IIFT: Neurology Mosaics, Instructions for the indirect immunofluorescence test. EUROIMMUN; FA_112d-1_A_UK_C13, 02/2019)
Immunoblot:
All steps are performed at ambient temperature (18-28 degrees C) utilizing the EUROBlot One instrument.
Diluted patient CSF (1:12.5) is added to test strips (strips containing recombinant antigen manufactured and purified using biochemical methods) in individual channels and incubated for 30 minutes. Positive CSF samples will bind to the purified recombinant antigen and negative CSF samples will not bind. Strips are washed to remove unbound antibodies and then are incubated with antihuman IgG antibodies (alkaline phosphatase-labelled) for 30 minutes. The strips are again washed to remove unbound antihuman IgG antibodies and nitroblue tetrazolium chloride/5-bromo-4-chloro-3-indolylphosphate (NBT/BCIP) substrate is added. Alkaline phosphatase enzyme converts the soluble substrate into a colored insoluble product on the membrane to produces a black band. Strips are digitized via picture capture on the EUROBlot One instrument and evaluated with the EUROLineScan software.(O'Connor K, Waters P, Komorowski L, et al: GABAA receptor autoimmunity: A multicenter experience. Neurol Neuroimmunol Neuroinflamm. 2019 Apr 4;6[3]:e552 doi: 10.1212/NXI.0000000000000552)
Fluorescence-Activated Cell Sorting Assay :
Human embryonic kidney cells (HEK 293) are transfected transiently with a plasmid (pIRES2- Aequorea coerulescens green fluorescent protein [AcGFP]) encoding both green fluorescent protein (AcGFP) and AQP4-M1. After 36 hours, a mixed population of cells (transfected expressing AQP4 on the surface and AcGFP in the cytoplasm and nontransfected lacking AQP4 and AcGFP) are lifted and resuspended in live cell-binding buffer. Patient CSF is then added to cells. After incubation and washing, the cells are resuspended in secondary antibody (AlexaFluor 647-conjugated goat-antihuman IgG), held on ice, washed, fixed, and analyzed by flow cytometry (BD FACSCanto; Becton, Dickinson and Co). Two populations are gated on the basis of AcGFP expression: positive (high AQP4 expression) and negative (low or no AQP4 expression). The IgG-binding index is calculated as the ratio of the average MFI for duplicate aliquots of each cell population (MFI GFP positive/MFI GFP negative). (Unpublished Mayo method)
Profile tests: Monday through Sunday; Reflex tests: Varies
This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.
86255 x 9
86053
86341
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
PCDEC | Peds Autoimm Enceph CNS, CSF | 101416-6 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
3852 | ANNA-1, CSF | 94356-3 |
36429 | Reflex Added | 77202-0 |
21631 | PCA-Tr, CSF | 94362-1 |
21702 | GAD65 Ab Assay, CSF | 94359-7 |
61513 | NMDA-R Ab CBA, CSF | 93502-3 |
61515 | GABA-B-R Ab CBA, CSF | 93426-5 |
38325 | NMO/AQP4-IgG FACS, CSF | 46718-3 |
64280 | LGI1-IgG CBA, CSF | 94288-8 |
64282 | CASPR2-IgG CBA, CSF | 94286-2 |
64929 | DPPX Ab IFA, CSF | 82989-5 |
64927 | mGluR1 Ab IFA, CSF | 94361-3 |
605156 | GFAP IFA, CSF | 94360-5 |
605132 | Peds Autoimmune CNS Interp, CSF | 69048-7 |
618906 | IFA Notes | 48767-8 |
Change Type | Effective Date |
---|---|
File Definition - Algorithm | 2023-01-31 |
Test Changes - Title | 2022-04-28 |
Test Status - Test Delay | 2021-04-15 |